Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Kato, Y. Ohta, Y. Suzumura, K. Kohda, H. Kimoto, Y. Kawazoe (1988)
Antitumor Activity and Neutrophil‐selective Hematopoietic Toxicity of Busulfan Analogs in MiceJapanese Journal of Cancer Research : Gann, 79
L. Borella, A. Green, R. Webster (1972)
Immunologic rebound after cessation of long-term chemotherapy in acute leukemia.Blood, 40 1
A. Yeager, Charlotte Shinn, Drew Pardoll (1991)
Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice.Blood, 78 12
Fitchen Jh, Cline Mj (1980)
The effect of granulopoietic stress in mice with "latent" bone marrow failure.Experimental hematology, 8 6
E. Tonner, H. Sewell, A. Thomson (1988)
Cancer-induced alterations in T-cell subsets in normal and cyclophosphamide-treated mice. A flow cytometric analysis.International archives of allergy and applied immunology, 85 2
D. Boggs, S. Boggs (1980)
The Effect of Graded, Single Doses of Busulfan on Murine Erythropoiesis 1Proceedings of the Society for Experimental Biology and Medicine, 163
T. Miale, G. Bloom (1975)
The significance of lymphocytosis in congenital hypoplastic anemia.The Journal of pediatrics, 87 4
G. Ottolander, J. Velde, Wil Veenhof, K. Kleiverda, H. Haak, P. Spaander (1982)
Busulphan aplasia in rabbits: a model for human aplastic anaemiaBritish Journal of Haematology, 51
I. Koza, O. Babušíková (1988)
Sequential development of chronic lymphocytic leukemia in a patient with polycythemia vera.Neoplasma, 35 1
M. Mitchell (1988)
Combining chemotherapy with biological response modifiers in treatment of cancer.Journal of the National Cancer Institute, 80 18
A. Morley, Kevin Trainor, Judith Remes (1976)
Residual Marrow Damage: Possible Explanation for Idiosyncrasy to ChloramphenicolBritish Journal of Haematology, 32
(1995)
Williams’ hematology
LA Elson, DAG Galton, M Till (1958)
The action of chlorambucil and busulphan on the haemopoietic organs of the ratBr J Haematol, 4
A. Morley, Kevin Trainor, Judith Blake (1975)
A primary stem cell lesion in experimental chronic hypoplastic marrow failure.Blood, 45 5
I. Addison (1973)
Immunosuppression with busulphan: the effect on spleen, marrow and thymus cells of miceEuropean Journal of Immunology, 3
L. Elson, D. Galton, M. Till (1958)
The Action of Chlorambucil (CB. 1348) and Busulphan (Myleran) on the Haemopoietic Organs of the RatBritish Journal of Haematology, 4
E Tonner, HF Sewell, AW Thomson (1988)
Cancer-induced alterations in T-cell subsets in normal and cyclophosphamide-treated miceInt Arch Appl Immund, 85
A. Papayannis, E. Nikiforakis, D. Aanagnostou-Keramida (2009)
Development of chronic lymphocytic leukaemia in a patient with polycythaemia vera.Scandinavian journal of haematology, 29 1
Sally Kinsey, J. Watts, Middlesex Hospital, London (1988)
Accurate automated leucocyte differential counts despite profound leucopenia.Journal of Clinical Pathology, 41
A Morley, K Holmes, I Forbes (1974)
Depletion of B lymphocytes in chronic hypoplastic marrow failure (aplastic anaermia)Aust NZ J Med, 4
E. Robin, M. Berman, N. Bhoopalam, H. Cohen, W. Fried (1981)
Induction of lymphomas in mice by busulfan and chloramphenicol.Cancer research, 41 9 Pt 1
C. Pugsley, I. Forbes, A. Morley (1978)
Immunologic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan.Blood, 51 4
PC Vincent (1986)
Drug-induced aplastic anaemia and agranulocytosis: incidence and mechanismsDrugs, 31
A. Morley, Judith Blake (1974)
An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan.Blood, 44 1
A. Hall, M. Tilby (1992)
Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.Blood reviews, 6 3
L. Wathen, R. DeGowin, D. Gibson, S. Knapp (1982)
Residual injury to the hemopoietic microenvironment following sequential radiation and busulfan.International journal of radiation oncology, biology, physics, 8 8
D. Brohée, P. Néve, M. Vanhaeverbeek, A. Lefevre (1991)
Is lymphopenia an obligatory side effect of all cancer chemotherapy treatmentsMedical Science Research, 19
N. Bhoopalam, K. Price, H. Norgello, W. Fried (1985)
Busulfan-induced suppression of natural killer cell activity.Experimental hematology, 13 11
C. Andrews, N. Spurling, J. Turton (1993)
Characterisation of busulphan-induced myelotoxicity in B6C3F1 mice using flow cytometryComparative Haematology International, 3
P. Gascón, N. Zoumbos, N. Young (1986)
Analysis of natural killer cells in patients with aplastic anemia.Blood, 67 5
L. Sabbe, H. Haak, J. Velde, B. Bradley, L. Bode, J. Blom, J. Rood (1984)
Immunological investigations in aplastic anemia patients.Acta haematologica, 71 3
LJM Sabbe, HL Haak, J Velde (1984)
Immunlogical investigations in aplastic anaemiaActa Haematol, 71
L. Elson (1955)
A Comparison of the Effects of Radiation and Radiomimetic Chemicals on the BloodBritish Journal of Haematology, 1
A. Morley, J. Blake (1974)
Haemopoietic precursor cells in experimental hypoplastic marrow failure.The Australian journal of experimental biology and medical science, 52 6
G. Santos, P. Tutschka (1974)
Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia.Journal of the National Cancer Institute, 53 6
D. Braun, J. Harris (1981)
Modulation of the immune response by chemotherapy.Pharmacology & therapeutics, 14 1
R. Irons, W. Stillman (1993)
Cell proliferation and differentiation in chemical leukemogenesisSTEM CELLS, 11
Dunn Cd (1974)
The chemical and biological properties of busulphan ("Myleran").Experimental hematology, 2 3
A. Morley, K. Holmes, I. Forbes (1974)
Depletion of B lymphocytes in chronic hypoplastic marrow failure (aplastic anaemia).Australian and New Zealand journal of medicine, 4 6
Female B6C3F1 mice (12–14 weeks old) were dosed with busulphan (BU) by the intraperitoneal route at a range of dose levels between 10 and 40 mg/kg on four occasions at 14 day intervals. Six weeks after the final dose, mice were given normal drinking water or drinking water containing chloramphenicol succinate (CAP.S) at 4 mg/ml. Animals were killed at eight timepoints after the final BU dose, the final samples being taken at day 485 or 497. A range of haematological parameters were determined and lymphocyte subsets analysed. The inclusion of CAP.S in the drinking water did not affect the changes to haematological parameters or lymphocyte subsets induced by BU. Lymphocyte count was reduced to 51%–66% of control values in animals receiving 40 mg BU/kg on all occasions except day 85. However, the lymphocyte count was increased to 107%–143% of control values in animals receiving 10 mg BU/kg on all occasions except day 85. The large unstained cell (LUC) count was reduced to between 25%–47% of control values in animals receiving 40 mg BU/kg on all occasions, however, the LUC count was not increased at low BU dosage. At day 485/497, B lymphocyte counts were reduced to 48% (p<0.01), 64% (NS) and 55% (p<0.05) of control values in mice treated with 40, 33 and 25 mg BU/kg, respectively. T lymphocyte counts were not affected by BU treatment. We have, therefore, demonstrated in the present study that administration of BU at high levels to the B6C3F1 mouse induces a long-lasting and specific depletion of peripheral B lymphocytes; also, BU at low dose levels causes a mild but persistent lymphocytosis.
Comparative Clinical Pathology – Springer Journals
Published: Jun 22, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.